

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 June 2003 (05.06.2003)

PCT

(10) International Publication Number  
**WO 03/045385 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/428**,  
31/429, 31/44, A61P 25/16, 25/28, C07D 277/82, 417/12,  
409/12, 477/12

(74) Agent: **POPPE, Regina**; Grenzacherstrasse 124,  
CH-4070 Basle (CH).

(21) International Application Number: PCT/EP02/12907

(22) International Filing Date:  
18 November 2002 (18.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
01127442.0 27 November 2001 (27.11.2001) EP

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


(71) Applicant: **F. HOFFMANN-LA ROCHE AG** [CH/CH];  
Grenzacherstrasse 124, CH-4070 Basle (CH).

(72) Inventors: **FLOHR, Alexander**; St. Galler-Ring 142,  
CH-4054 Basle (CH). **JAKOB-ROETNE, Roland**;  
Oberer Baselblick 37, 79595 Inzlingen (DE). **NOR-  
CROSS, Roger, David**; Alte Saline 20, CH-4310  
Rheinfelden (CH). **RIEMER, Claus**; Optizstrasse 5,  
79110 Freiburg (DE).

**Published:**  
— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BENZOTHAIAZOLE DERIVATIVES



(57) Abstract: The invention relates to compounds of the general formula (I) wherein, R is hydrogen,  $-(CH_2)_n$ -phenyl, optionally substituted by halogen, lower alkyl, lower alkoxy, trifluoromethyl or  $-N(R')$ -C(O)-lower alkyl,  $-(CH_2)_n$ -pyridinyl, optionally substituted by lower alkyl,  $-(CH_2)_n$ -C<sub>3-6</sub>-cycloalkyl, optionally substituted by hydroxy,  $-(CH_2)_n$ -N(R')-C<sub>3-6</sub>-cycloalkyl,  $-(CH_2)_n$ -benzo[1,3]-dioxolyl,  $-(CR'_2)_n$ -thiophenyl, optionally substituted by lower alkyl,  $-(CR'_2)_n$ -thiazolyl, optionally substituted by lower alkyl,  $-(CH_2)_n$ -C(O)-thiophenyl, optionally substituted by halogen,  $-(CH_2)_n$ -furanlyl, optionally substituted by lower alkyl,  $-(CH_2)_n$ -C(O)-(CH<sub>2</sub>)<sub>n</sub>-thiophenyl,  $-(CHR')$ -benzofuran-2-yl,  $-(CH_2)_n$ -benzo[b]thiophenyl, optionally substituted by lower alkyl,  $-(CH_2)_n$ -N(R')-C(O)-phenyl, optionally substituted by halogen or lower alkoxy,  $-(CH_2)_n$ -C(O)-phenyl, optionally substituted by lower alkoxy,  $-(CH_2)_n$ -C(O)-2,3-dihydro-benzo [1,4]dioxin-6-yl,  $-(CH_2)_n$ -N(R')-C(O)-pyridinyl,  $-(CH_2)_n$ -tetrahydrofuranyl,


$-(CH_2)_n$ -bi-phenyl,  $-(CH_2)_n$ -CH(phenyl)-pyridinyl,  $-(CH_2)_n$ -1-oxo-1,3-dihydro-isoindol-2-yl,  $-(CH_2)_n$ -1,3-dioxo-1,3-dihydro-isoindol-2-yl,  $-(CH_2)_n$ -CH(phenyl)-tetrahydropyranyl,  $-(CH_2)_n$ -1-oxo-1,2,3,4-tetrahydro-isoquinolin-3-yl or  $(CH_2)_n$ -S-[1,3,4]thiazol-2-yl, optionally substituted by amino; R' is hydrogen or lower alkyl, independently from each other in case R'<sub>2</sub>; and n is 0, 1, 2, 3 or 4; and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I have a good affinity to the A<sub>2A</sub> receptor and they are therefore useful for the treatment of diseases, related to this receptor.

WO 03/045385 A1

Case 21015

Benzothiazole derivatives

The present invention relates to compounds of the general formula



wherein

R is

hydrogen,

-(CH<sub>2</sub>)<sub>n</sub>-phenyl, optionally substituted by halogen, lower alkyl, lower alkoxy, trifluoromethyl or -N(R')-C(O)-lower alkyl,

-(CH<sub>2</sub>)<sub>n</sub>-pyridinyl, optionally substituted by lower alkyl,

-(CH<sub>2</sub>)<sub>n</sub>-C<sub>3-6</sub>-cycloalkyl, optionally substituted by hydroxy,

-(CH<sub>2</sub>)<sub>n</sub>-N(R')-C<sub>3-6</sub>-cycloalkyl, optionally substituted by hydroxy,

-(CH<sub>2</sub>)<sub>n</sub>-benzo[1,3]-dioxolyl,

-(CR'<sub>2</sub>)<sub>n</sub>-thiophenyl, optionally substituted by lower alkyl,

-(CR'<sub>2</sub>)<sub>n</sub>-thiazolyl, optionally substituted by lower alkyl,

-(CH<sub>2</sub>)<sub>n</sub>-C(O)-thiophenyl, optionally substituted by halogen,

-(CH<sub>2</sub>)<sub>n</sub>-furanly, optionally substituted by lower alkyl,

-(CH<sub>2</sub>)<sub>n</sub>-C(O)-(CH<sub>2</sub>)<sub>n</sub>-thiophenyl,

-(CHR')<sub>n</sub>-benzofuran-2-yl,

-(CH<sub>2</sub>)<sub>n</sub>-benzo[b]thiophenyl, optionally substituted by lower alkyl,

-(CH<sub>2</sub>)<sub>n</sub>-N(R')-C(O)-phenyl, optionally substituted by halogen or lower alkoxy,

-(CH<sub>2</sub>)<sub>n</sub>-C(O)-phenyl, optionally substituted by lower alkoxy,

-(CH<sub>2</sub>)<sub>n</sub>-C(O)-2,3-dihydro-benzo[1,4]dioxin-6-yl,

-(CH<sub>2</sub>)<sub>n</sub>-N(R')-C(O)-pyridinyl,

-(CH<sub>2</sub>)<sub>n</sub>-tetrahydrofuranly,

-CH-bi-phenyl,

-CH(phenyl)-pyridinyl,  
 -(CH<sub>2</sub>)<sub>n</sub>-1-oxo-1,3-dihydro-isoindol-2-yl,  
 -(CH<sub>2</sub>)<sub>n</sub>-1,3-dioxo-1,3-dihydro-isoindol-2-yl,  
 -(CH<sub>2</sub>)<sub>n</sub>-CH(phenyl)-tetrahydropyranyl,  
 5 -(CH<sub>2</sub>)<sub>n</sub>-1-oxo-1,2,3,4-tetrahydro-isoquinolin-3-yl or  
 -(CH<sub>2</sub>)<sub>n</sub>-S-[1,3,4]thiazol-2-yl, optionally substituted by amino;

R' is hydrogen or lower alkyl, independently from each other in case R'<sub>2</sub>; and

n is 0, 1, 2, 3 or 4

and to pharmaceutically acceptable acid addition salts thereof.

10 It has surprisingly been found that the compounds of general formula I are adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A<sub>2A</sub>-receptor and a high selectivity to the A<sub>1</sub>- and A<sub>3</sub> receptors.

Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first  
 15 reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive nucleotides adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and cyclic adenosine monophosphate (cAMP); to the biochemical methylating agent S-adenosyl-L-methione (SAM); and structurally to the coenzymes NAD, FAD and coenzyme A; and to RNA. Together adenosine and these related compounds are  
 20 important in the regulation of many aspects of cellular metabolism and in the modulation of different central nervous system activities.

The receptors for adenosine have been classified as A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub> receptors, belonging to the family of G protein-coupled receptors. Activation of adenosine receptors by adenosine initiates signal transduction mechanism. These mechanisms are dependent  
 25 on the receptor associated G protein. Each of the adenosine receptor subtypes has been classically characterised by the adenylate cyclase effector system, which utilises cAMP as a second messenger. The A<sub>1</sub> and A<sub>3</sub> receptors, coupled with G<sub>i</sub> proteins inhibit adenylate cyclase, leading to a decrease in cellular cAMP levels, while A<sub>2A</sub> and A<sub>2B</sub> receptors couple to G<sub>s</sub> proteins and activate adenylate cyclase, leading to an increase in cellular cAMP levels. It  
 30 is known that the A<sub>1</sub> receptor system include the activation of phospholipase C and modulation of both potassium and calcium ion channels. The A<sub>3</sub> subtype, in addition to its association with adenylate cyclase, also stimulates phospholipase C and so activates calcium ion channels.

The A<sub>1</sub> receptor (326-328 amino acids) was cloned from various species (canine, human, rat, dog, chick, bovine, guinea-pig) with 90–95 % sequence identify among the mammalian species. The A<sub>2A</sub> receptor (409-412 amino acids) was cloned from canine, rat, human, guinea pig and mouse. The A<sub>2B</sub> receptor (332 amino acids) was cloned from  
5 human and mouse with 45 % homology of human A<sub>2B</sub> with human A<sub>1</sub> and A<sub>2A</sub> receptors. The A<sub>3</sub> receptor (317-320 amino acids) was cloned from human, rat, dog, rabbit and sheep.

The A<sub>1</sub> and A<sub>2A</sub> receptor subtypes are proposed to play complementary roles in adenosine's regulation of the energy supply. Adenosine, which is a metabolic product of ATP, diffuses from the cell and acts locally to activate adenosine receptors to decrease the  
10 oxygen demand (A<sub>1</sub>) or increase the oxygen supply (A<sub>2A</sub>) and so reinstate the balance of energy supply: demand within the tissue. The actions of both subtypes is to increase the amount of available oxygen to tissue and to protect cells against damage caused by a short term imbalance of oxygen. One of the important functions of endogenous adenosine is preventing damage during traumas such as hypoxia, ischaemia, hypotension and seizure  
15 activity.

Furthermore, it is known that the binding of the adenosine receptor agonist to mast cells expressing the rat A<sub>3</sub> receptor resulted in increased inositol triphosphate and intracellular calcium concentrations, which potentiated antigen induced secretion of inflammatory mediators. Therefore, the A<sub>3</sub> receptor plays a role in mediating asthmatic  
20 attacks and other allergic responses.

Adenosine is a neuromodulator, able to modulate many aspects of physiological brain function. Endogenous adenosine, a central link between energy metabolism and neuronal activity, varies according to behavioural state and (patho)physiological conditions. Under conditions of increased demand and decreased availability of energy  
25 (such as hypoxia, hypoglycemia, and/or excessive neuronal activity), adenosine provides a powerful protective feedback mechanism. Interacting with adenosine receptors represents a promising target for therapeutic intervention in a number of neurological and psychiatric diseases such as epilepsy, sleep, movement disorders (Parkinson or Huntington's disease), Alzheimer's disease, depression, schizophrenia, or addiction. An increase in  
30 neurotransmitter release follows traumas such as hypoxia, ischaemia and seizures. These neurotransmitters are ultimately responsible for neural degeneration and neural death, which causes brain damage or death of the individual. The adenosine A<sub>1</sub> agonists which mimic the central inhibitory effects of adenosine may therefore be useful as neuroprotective agents. Adenosine has been proposed as an endogenous anticonvulsant  
35 agent, inhibiting glutamate release from excitory neurons and inhibiting neuronal firing. Adenosine agonists therefore may be used as antiepileptic agents. Adenosine antagonists stimulate the activity of the CNS and have proven to be effective as cognition enhancers.

Selective A<sub>2a</sub> antagonists have therapeutic potential in the treatment of various forms of dementia, for example in Alzheimer's disease, and of neurodegenerative disorders, e.g. stroke. Adenosine A<sub>2a</sub> receptor antagonists modulate the activity of striatal GABAergic neurons and regulate smooth and well-coordinated movements, thus offering a potential therapy for Parkinsonian symptoms. Adenosine is also implicated in a number of physiological processes involved in sedation, hypnosis, schizophrenia, anxiety, pain, respiration, depression, and drug addiction (amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids). Drugs acting at adenosine receptors therefore have therapeutic potential as sedatives, muscle relaxants, antipsychotics, anxiolytics, analgesics, respiratory stimulants, antidepressants, and to treat drug abuse. They may also be used in the treatment of ADHD (attention deficit hyper-activity disorder).

An important role for adenosine in the cardiovascular system is as a cardioprotective agent. Levels of endogenous adenosine increase in response to ischaemia and hypoxia, and protect cardiac tissue during and after trauma (preconditioning). By acting at the A<sub>1</sub> receptor, adenosine A<sub>1</sub> agonists may protect against the injury caused by myocardial ischemia and reperfusion. The modulating influence of A<sub>2a</sub> receptors on adrenergic function may have implications for a variety of disorders such as coronary artery disease and heart failure. A<sub>2a</sub> antagonists may be of therapeutic benefit in situations in which an enhanced antiadrenergic response is desirable, such as during acute myocardial ischemia. Selective antagonists at A<sub>2a</sub> receptors may also enhance the effectiveness of adenosine in terminating supraventricular arrhythmias.

Adenosine modulates many aspects of renal function, including renin release, glomerular filtration rate and renal blood flow. Compounds which antagonise the renal effects of adenosine have potential as renal protective agents. Furthermore, adenosine A<sub>3</sub> and/or A<sub>2B</sub> antagonists may be useful in the treatment of asthma and other allergic responses or and in the treatment of diabetes mellitus and obesity.

Numerous documents describe the current knowledge on adenosine receptors, for example the following publications:

- Bioorganic & Medicinal Chemistry, 6, (1998), 619-641,
- Bioorganic & Medicinal Chemistry, 6, (1998), 707-719,
- J. Med. Chem., (1998), 41, 2835-2845,
- J. Med. Chem., (1998), 41, 3186-3201,
- J. Med. Chem., (1998), 41, 2126-2133,
- J. Med. Chem., (1999), 42, 706-721,
- J. Med. Chem., (1996), 39, 1164-1171,
- Arch. Pharm. Med. Chem., 332, 39-41, (1999),

Am. J. Physiol., 276, H1113-1116, (1999) or  
Naunyn Schmied, Arch. Pharmacol. 362, 375-381, (2000).

Objects of the present invention are the compounds of formula I per se, the use of  
compounds of formula I and their pharmaceutically acceptable salts for the manufacture of  
5 medicaments for the treatment of diseases, related to the adenosine A<sub>2</sub> receptor, their  
manufacture, medicaments based on a compound in accordance with the invention and  
their production as well as the use of compounds of formula I in the control or prevention  
of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease,  
Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain,  
10 respiration deficits, depression, drug addiction, such as amphetamine, cocaine, opioids,  
ethanol, nicotine, cannabinoids, or against asthma, allergic responses, hypoxia, ischaemia,  
seizure and substance abuse. Furthermore, compounds of the present invention may be  
useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and  
cardioprotective agents for disorders such as coronary artery disease and heart failure. The  
15 most preferred indications in accordance with the present invention are those, which base  
on the A<sub>2A</sub> receptor antagonistic activity and which include disorders of the central nervous  
system, for example the treatment or prevention of Alzheimer's disease, certain depressive  
disorders, drug addiction, neuroprotection and Parkinson's disease as well as ADHD.

As used herein, the term "lower alkyl" denotes a saturated straight- or branched-  
20 chain alkyl group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl,  
isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred lower alkyl groups are  
groups with 1 - 4 carbon atoms.

The term "halogen" denotes chlorine, iodine, fluorine and bromine.

The term "lower alkoxy" denotes a group wherein the alkyl residues is as defined  
25 above, and which is attached via an oxygen atom.

The term "pharmaceutically acceptable acid addition salts" embraces salts with  
inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid,  
phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic  
acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.

30 Preferred compounds of the present application are compounds of formula I,  
wherein R is hydrogen, for example the following compound:  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid amide.

Further preferred are compounds of formula I, wherein R is  $-(CH_2)_n$ -phenyl, optionally substituted by halogen, lower alkoxy or lower alkyl, for example the following compounds:

- 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid phenethyl-amide,  
5 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 3-chloro-benzylamide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 2-chloro-benzylamide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 2-methoxy-benzylamide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide,  
10 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide,  
15 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(2-chloro-phenyl)-ethyl]-amide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide,  
20 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide or  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-m-tolyl-ethyl)-amide.

Further preferred are compounds, wherein R is  $-(CH_2)_n$ -pyridinyl, for example the following compounds:

- 25 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid pyridin-3-ylamide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (pyridin-2-ylmethyl)-amide  
or  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide.

- 30 Further preferred are compounds, wherein R is  $-(CHR')_n$ -thiophenyl or  $-(CH_2)_n$ -C(O)-thiophenyl, optionally substituted by halogen, for example the following compounds:

- 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-thiophen-2-yl-ethyl)-amide,  
35 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-thiophen-3-yl-ethyl)-

amide,

4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-chloro-thiophen-2-yl)-2-oxo-ethyl]-amide or


4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (1-methyl-2-thiophen-2-yl-ethyl)-amide.

A preferred group of compounds is further those, wherein R is  $-(CHR')_n$ -thiazolyl, optionally substituted by lower alkyl, for example the following compound:

4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [1-(4-methyl-thiazol-2-yl)-ethyl]-amide.

The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes described below, which processes comprise


a) reacting a compound of formula



with a compound of formula



to a compound of formula




wherein R is as defined above, or


b) cyclising a compound of formula



- 8 -



to a compound of formula



wherein R is as described above, and


- 5 if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

The compounds of formula I may be prepared in accordance with process variants a) and b) and with the following schemes 1 and 2. The preparation of 84 Examples is further described in more detail.

10

15

Scheme 1



wherein R is as described above and CDI is 1,1'-carbonyl-diimidazole.

The preparation of the starting compound of formula (1) has been described in  
 5 WO 01/97786.

In accordance with scheme 1, the compounds of formula I are prepared as follows:


Diethyl oxalate (2) is heated to about 120 °C. 2-Methoxy-5-morpholin-4-yl-phenylamine  
 (1) is added very cautiously in small quantities and the mixture is heated for 90 minutes at  
 about 180 °C. After cooling to room temperature and filtration n-hexane is added. The  
 10 resulting precipitate is collected by filtration. After washing with hexane and drying N-(2-  
 methoxy-5-morpholin-4-yl-phenyl)-oxalamide ethyl ester (3) is obtained. Then, to the  
 obtained compound of formula (3) in boiling xylene is added phosphorus pentasulfide in

small portions over a period of about 30 minutes. The mixture is refluxed for about 5 hours, cooled to room temperature and filtered. The solution is extracted with 1N NaOH. The aqueous phase is washed with toluene, filtered, and treated at 0-5 °C with concentrated hydrochloric acid until pH 1 was reached. Filtration of the precipitate yielded (2-methoxy-5-morpholin-4-yl-phenylamino)-thioxo-acetic acid (4).

A solution of (2-methoxy-5-morpholin-4-yl-phenylamino)-thioxo-acetic acid (4) in 1N NaOH is added to a solution of potassium ferricyanide in water at a rate that the temperature does not exceed 10 °C. The mixture is stirred for 3 hours at 10 °C and concentrated hydrochloric acid is added until pH 1 was reached. Filtration of the precipitate and drying yielded 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (5). A suspension of the compound of formula (5) and 1,1'-carbonyl-diimidazole in dimethylformamide is stirred at room temperature for about one hour. A compound of formula (6), for example benzylamine, is added, stirring is continued and after about 20 hours water is added. After extraction with ethyl acetate and chromatography on silicagel with dichloromethane/ethylacetate is yielded a compound of formula I.

According to scheme 1, examples 3 to example 84 have been prepared.

Scheme 2



wherein R is as defined above.

In accordance with scheme 2 the corresponding chloroacetamide of formula (7) and sulfur in dimethylformamide are treated with triethylamine, and the mixture is stirred for about 15 hours at room temperature. Then 2-methoxy-5-morpholin-4-yl-phenylamine (1) and n-propanol are added and stirring at room temperature is continued for 6 hours. The mixture is refluxed for two days. The precipitated crystals are filtered off and washed with n-propanol to yield a compound of formula (8).

A suspension of the compound of formula (8) in 1N aqueous sodiumhydroxide is added to a solution of potassium ferricyanide in water. The mixture is stirred at 50 °C for about 30 minutes and then at room temperature overnight. The precipitate is separated by filtration, dissolved in dichloromethane and purified by column chromatography on silicagel with ethylacetate/hexane to yield a compound of formula I.

According to scheme 2, examples 1 and 2 have been prepared.

#### Isolation and purification of the compounds

Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the Preparations and Examples herein below. However, other equivalent separation or isolation procedures could, of course, also be used.

#### Salts of compounds of formula I

The compounds of formula I may be basic, for example in cases where the residue R contains a basic group such as an aliphatic or aromatic amine moiety. In such cases the compounds of Formula I may be converted to a corresponding acid addition salt.

The conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Typically, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent. The

temperature is maintained between 0 °C and 50 °C. The resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.

The acid addition salts of the basic compounds of Formula I may be converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable  
5 base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.

The compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are adenosine receptor ligands and possess a high affinity towards the  
10 adenosine A<sub>2A</sub> receptor and a good selectivity towards A<sub>1</sub> and A<sub>3</sub> receptors.

The compounds were investigated in accordance with the tests given hereinafter.

#### Human adenosine A<sub>1</sub> receptor

The human adenosine A<sub>1</sub> receptor was recombinantly expressed in chinese hamster ovary (CHO) cells using the semliki forest virus expression system. Cells were harvested,  
15 washed twice by centrifugation, homogenised and again washed by centrifugation. The final washed membrane pellet was suspended in a Tris (50 mM) buffer containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl<sub>2</sub> and 10 mM MgCl<sub>2</sub> (pH 7.4) (buffer A). The [<sup>3</sup>H]-DPCPX ([propyl-<sup>3</sup>H]8-cyclopentyl-1,3-dipropylxanthine; 0.6 nM) binding assay was carried out in 96-well plates in the presence of 2.5 µg of membrane protein, 0.5 mg of Ysi-poly-l-lysine  
20 SPA beads and 0.1 U adenosine deaminase in a final volume of 200 µl of buffer A. Non-specific binding was defined using xanthine amine congener (XAC; 2 µM). Compounds were tested at 10 concentrations from 10 µM - 0.3 nM. All assays were conducted in duplicate and repeated at least two times. Assay plates were incubated for 1 hour at room temperature before centrifugation and then bound ligand determined using a Packard  
25 Topcount scintillation counter. IC<sub>50</sub> values were calculated using a non-linear curve fitting program and Ki values calculated using the Cheng-Prusoff equation.

#### Human adenosine A<sub>2A</sub> receptor

The human adenosine A<sub>2A</sub> receptor was recombinantly expressed in chinese hamster ovary (CHO) cells using the semliki forest virus expression system. Cells were harvested,  
30 washed twice by centrifugation, homogenised and again washed by centrifugation. The final washed membrane pellet was suspended in a Tris (50 mM) buffer containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl<sub>2</sub> and 10 mM MgCl<sub>2</sub> (pH 7.4) (buffer A). The [<sup>3</sup>H]-SCH-58261 (Dionisotti et al., 1997, Br J Pharmacol 121, 353; 1nM) binding assay was carried out in 96-well plates in the presence of 2.5 µg of membrane protein, 0.5 mg of Ysi-poly-l-lysine

SPA beads and 0.1 U adenosine deaminase in a final volume of 200  $\mu$ l of buffer A. Non-specific binding was defined using xanthine amine congener (XAC; 2  $\mu$ M). Compounds were tested at 10 concentrations from 10  $\mu$ M - 0.3 nM. All assays were conducted in duplicate and repeated at least two times. Assay plates were incubated for 1 hour at room temperature before centrifugation and then bound ligand determined using a Packard Topcount scintillation counter. IC<sub>50</sub> values were calculated using a non-linear curve fitting program and Ki values calculated using the Cheng-Prusoff equation.

It has been shown that compounds of formula I have a good affinity to the A<sub>2A</sub> receptor and a high selectivity toward the A<sub>1</sub>. The preferred compounds show a pKi > 7.5.

Example No.	hA <sub>1</sub> (pKi)	hA <sub>2</sub> (pKi)
1	5.4	7.6
6	5.9	7.7
9	5.4	7.8
13	5.2	7.5
15	5.6	7.7
16	5.4	7.5
22	5.9	8.4
25	5.1	7.6
49	5.8	7.5
54	5.9	8.2
55	5.2	7.6
57	5.8	7.7
59	5.2	7.5
62	5.7	7.5
63	6.0	7.7

64	5.9	7.6
65	6.3	7.6
71	5.9	7.6
73	5.8	7.5
77	6.3	8.3
81	6.7	8.9

The compounds of formula I and the pharmaceutically acceptable salts of the compounds of formula I can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions.

The compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts and, if desired, one or

more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.

In accordance with the invention compounds of formula I as well as their pharmaceutically acceptable salts are useful in the control or prevention of illnesses based on the adenosine receptor antagonistic activity, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents and for the production of corresponding medicaments.

The most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or prevention of certain depressive disorders, neuroprotection and Parkinson's disease.

The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.

#### 20 Tablet Formulation (Wet Granulation)

<u>Item</u>	<u>Ingredients</u>	<u>mg/tablet</u>			
		5 mg	25 mg	100 mg	500 mg
1.	Compound of formula I	5	25	100	500
2.	Lactose Anhydrous DTG	125	105	30	150
25 3.	Sta-Rx 1500	6	6	6	30
4.	Microcrystalline Cellulose	30	30	30	150
5.	Magnesium Stearate	1	1	1	1
	Total	167	167	167	831

#### Manufacturing Procedure

- 30 1. Mix items 1, 2, 3 and 4 and granulate with purified water.
2. Dry the granules at 50°C.



3. Pass the granules through suitable milling equipment.
4. Add item 5 and mix for three minutes; compress on a suitable press.

#### Capsule Formulation

	<u>Item</u>	<u>Ingredients</u>	<u>mg/capsule</u>			
			5 mg	25 mg	100 mg	500 mg
5						
	1.	Compound of formula I	5	25	100	500
	2.	Hydrous Lactose	159	123	148	---
	3.	Corn Starch	25	35	40	70
	4.	Talc	10	15	10	25
10	5.	Magnesium Stearate	1	2	2	5
		Total	200	200	300	600

#### Manufacturing Procedure

1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes.
- 15 3. Fill into a suitable capsule.

The following preparation and examples illustrate the invention but are not intended to limit its scope.

#### Example 1

##### 4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid amide

##### 20 a) 2-(2-Methoxy-5-morpholin-4-yl-phenylamino)-2-thioxo-acetamide

- 173 mg (1.85 mmol) Chloroacetamide and 119 mg (3.70 mmol) sulfur in 2 ml dimethylformamide were treated with 772  $\mu$ l (5.55 mmol) triethylamine and the mixture was stirred for 15 hours at room temperature. Then 385 mg (1.85 mmol) 2-methoxy-5-morpholin-4-yl-phenylamine and 10 ml n-propanol were added and stirring at room
- 25 temperature was continued for 6 hours. The mixture was refluxed for two days. The precipitated crystals were filtered off and washed with n-propanol to yield 320 mg (59 %) 2-(2-methoxy-5-morpholin-4-yl-phenylamino)-2-thioxo-acetamide as red-brown crystals.
- MS m/e (%): 296 (M+H<sup>+</sup>, 100),
- MA: C<sub>13</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>S (295.357) calc.: C 52.87 H 5.80 N 14.23 S 10.86
- 30 found: C 52.38 H 5.82 N 13.85 S 10.86

b) 4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid amide

A suspension of 220 mg (0.75 mmol) 2-(2-methoxy-5-morpholin-4-yl-phenylamino)-2-thioxo-acetamide in 2.88 ml 1N aqueous sodiumhydroxide was added to a solution of 813 mg ( 2.47 mmol) potassium ferricyanide in 2 ml water. The mixture was stirred at 50 °C for 30 minutes and then at room temperature overnight. The precipitate was separated by filtration, dissolved in dichloromethane and purified by column chromatography on silicagel with ethylacetate/hexane 1/1. 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid amide, 32 mg (15 %), was obtained as yellow crystals with mp.: 228-230 °C, MS m/e (%): 294 (M+H<sup>+</sup>, 100).

Example 2

4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (4-fluoro-phenyl)-amide

a) N-(4-Fluoro-phenyl)-2-(2-methoxy-5-morpholin-4-yl-phenylamino)-2-thioxo-acetamide

919 mg (4.80 mmol) α-chloro-4-fluoroacetanilide and 308 mg (9.60 mmol) sulfur in 10 ml dimethylformamide were treated with 2.01 ml (14.4 mmol) triethylamine and the mixture was stirred for 2 days at room temperature. Then 1.00 g (4.80 mmol) 2-methoxy-5-morpholin-4-yl-phenylamine in 5 ml dimethylformamide and 25 ml n-propanol were added and stirring at room temperature was continued for 6 hours. The mixture was refluxed for 6.5 hours. The precipitated crystals were filtered off and washed with water and dried to yield 434 mg (24 %) N-(4-fluoro-phenyl)-2-(2-methoxy-5-morpholin-4-yl-phenylamino)-2-thioxo-acetamide as red powder with mp.: 206-208 °C, MS m/e (%): 390 (M+H<sup>+</sup>, 100).

b) 4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (4-fluoro-phenyl)-amide

A suspension of 100 mg (0.26 mmol) N-(4-fluoro-phenyl)-2-(2-methoxy-5-morpholin-4-yl-phenylamino)-2-thioxo-acetamide in 3.60 ml 1N aqueous sodiumhydroxide was added to a solution of 285 mg ( 0.87 mmol) potassium ferricyanide in 1 ml water. The mixture was stirred at 50 °C for two days and then extracted with dichloromethane. Purification by column chromatography on silicagel with ethylacetate/hexane 3/7 yielded 3.5 mg 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (4-fluoro-phenyl)-amide as off-white crystals, MS m/e (%): 388 (M+H<sup>+</sup>, 100)

Example 3

4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid benzylamide

a) N-(2-Methoxy-5-morpholin-4-yl-phenyl)-oxalamic acid ethyl ester

139 ml (1015 mmol) Diethyl oxalate were heated to 120 °C. 30.3 g (145 mmol) 2-methoxy-5-morpholin-4-yl-phenylamine were added very cautiously in small quantities and the mixture was heated for 90 minutes at 180 °C. After cooling to room temperature and  
5 filtration 1.5 l n-hexane were added. The resulting precipitate was collected by filtration. After washing with hexane and drying 34.4 g (77 %) N-(2-methoxy-5-morpholin-4-yl-phenyl)-oxalamic acid ethyl ester was obtained as greenish crystals, mp.: 95-97 °C, MS m/e (%): 309 (M+H<sup>+</sup>, 100).

b) (2-Methoxy-5-morpholin-4-yl-phenylamino)-thioxo-acetic acid

10 To 33.9g (110 mmol) N-(2-methoxy-5-morpholin-4-yl-phenyl)-oxalamic acid ethyl ester in 652 ml boiling xylene were added 8.80 g (40 mmol) phosphorus pentasulfide in small portions over a period of 30 minutes. The mixture was refluxed for 5 hours, cooled to room temperature and filtered. The solution was extracted 7 times with 100 ml 1N NaOH. The aqueous phase was washed twice with 100 ml toluene, filtered, and treated at 0-5 °C  
15 with concentrated hydrochloric acid until pH 1 was reached. Filtration of the precipitate yielded 20.2 g (62 %) (2-methoxy-5-morpholin-4-yl-phenylamino)-thioxo-acetic acid as yellow crystals with mp.: 156-158 °C, MS m/e (%): 297 (M+H<sup>+</sup>, 100).






c) 4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid







A solution of 10.5 g (35.4 mmol) (2-methoxy-5-morpholin-4-yl-phenylamino)-thioxo-acetic acid in 248 ml (248 mmol) 1N NaOH was added dropwise to a solution of 40.1 g (119 mmol) potassium ferricyanide in 119 ml water at a rate that the temperature did not exceed 10 °C. The mixture was stirred for 3 hours at 10 °C and concentrated hydrochloric acid was added until pH 1 was reached. Filtration of the precipitate and drying yielded 8.80 g (84 %) 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid as yellow crystals  
25 with mp.: 99-100 °C, MS m/e (%): 295 (M+H<sup>+</sup>, 100).







d) 4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid benzylamide







A suspension of 29.4 mg (0.10 mmol) 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid and 18.4 mg (0.11 mmol) 1.1'-carbonyl-diimidazole in 3 ml dimethylformamide was stirred at room temperature for one hour. 12.1 µl (0.11 mmol)  
30 benzylamine were added, stirring was continued and after 20 hours 15 ml water were added. Extraction with ethyl acetate and chromatography on silicagel with dichloromethane/ethylacetate 95/5 yielded 31.2 mg (41 %) of yellow 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid benzylamide with mp.: 156-158 °C, MS m/e (%): 384 (M+H<sup>+</sup>, 100).







According to example 3d derivatives have been synthesised. They are compiled in the following list comprising example 4 to example 81:

Exp. No.	Structure	Systematic name	m.p. °C	educt
4		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid phenylamide	190-191	Aniline
5		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid cyclohexylamide	146-147	Cyclohexyl-amine
6		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid phenethyl-amide	50-51	Phenylethyl-amine
7		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 4-chloro-benzylamide	175-176	4-Chloro-benzylamine
8		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid cyclopentylamide	174-175	Cyclopentyl-amine







9		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid pyridin-3-ylamide	220-221	3-Amino-pyridin
10		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (4-methoxy-phenyl)-amide	148	p-Anisidin
11		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (3-methoxy-phenyl)-amide	160	m-Anisidin
12		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-methoxy-phenyl)-amide	191	o-Anisidin
13		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (pyridin-2-ylmethyl)-amide	181-182	2-Amino-methyl-pyridine
14		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	190-193	1,3-Benzo-dioxole-5-methyl-amine







15		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 3-chloro-benzylamide	148-150	3-Chloro-benzylamine
16		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 2-chloro-benzylamide	114-116	2-Chloro-benzylamine
17		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 4-fluoro-benzylamide	155-156	4-Fluoro-benzylamine
18		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (pyridin-3-ylmethyl)-amide	181-184	3-(Amino-methyl)-pyridine
19		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid pyridin-2-ylamide	177-181	2-Amino-pyridine
20		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 3-fluoro-benzylamide	152-153	3-Fluoro-benzylamine

21		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 2-fluoro-benzylamide	133-134	2-Fluoro-benzylamine
22		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-thiophen-2-yl-ethyl)-amide	120-121	2-(2-Thienyl)-ethylamine
23		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (thiophen-2-ylmethyl)-amide	174-175	2-Thiophen-methylamine
24		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid cyclopropylmethyl-amide	152-153	(Amino-methyl)-cyclopropane
25		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 2-methoxy-benzylamide	186-188	2-Methoxy-benzylamine
26		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 4-methoxy-benzylamide	164-168	4-Methoxy-benzylamine







27		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 3-methoxy-benzylamide	140-144	3-Methoxy-benzylamine
28		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(4-chloro-benzoylamino)-ethyl]-amide	237-240	N-(2-Aminoethyl)-p-chloro-benzamide
29		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(1-oxo-1,3-dihydro-isoindol-2-yl)-ethyl]-amide	199-205	2-(2-Aminoethyl)-phthal-imidine
30		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (4-phenyl-tetrahydro-pyran-4-ylmethyl)-amide	144-148	4-Phenyl-4-methyl-amino-tetrahydro-pyran
31		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (pyridin-4-ylmethyl)-amide	207-209	4-Picolylamine
32		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propyl]-amide	200-202	N-(3-Amino-propyl)-phthalimide















33		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-amide	114-118	N-(4-Amino-butyl)-phthalimide
34		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-amide	231-233	N-(2-Amino-ethyl)-phthalimide
35		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid cyclohexylmethylamide	150-151	Cyclohexyl-methylamine
36		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (1-oxo-1,2,3,4-tetrahydro-isoquinolin-3-ylmethyl)-amide	152-155	3-(Amino-methyl)-3,4-dihydro-1(2H)-isoquinolinone
37		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(2-methoxy-benzoylamino)-ethyl]-amide	180-183	N-(2-Aminoethyl)-o-anisamide
38		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-pyridin-2-yl-ethyl)-amide	184-185	2-(2-Pyridyl)-ethylamine







39		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-oxo-2-phenyl-ethyl)-amide	197-200	Aminoacetophenone
40		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (3-phenyl-propyl)-amide	147	3-Phenyl-propylamine
41		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide	171-172	Tetrahydro-furfuryl-amine
42		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-hydroxy-cyclohexylmethyl)-amide	178-180	cis-2-Amino-ethyl-1-cyclohexanol
43		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-hydroxy-cyclohexylmethyl)-amide	133-135	trans-2-Aminoethyl-1-cyclo-hexanol
44		Nicotinic acid N'-(4-methoxy-7-morpholin-4-yl-benzothiazole-2-carbonyl)-hydrazide	222-224	Nicotinic acid hydrazide

45		Isonicotinic acid N'-(4-methoxy-7-morpholin-4-yl-benzothiazole-2-carbonyl)-hydrazide	171-174	Isonicotinic acid hydrazide
46		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid N'-benzoyl-hydrazide	>260°C	Benz-hydrazide
47		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid benzhydryl-amide	166-168	alpha-Amino-diphenyl-methane
48		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-pyridin-4-yl-ethyl)-amide	185-188	4-(2-Aminoethyl)-pyridine
49		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide	158-160	2-(2-Methoxy-phenyl)-ethylamine
50		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-acetylamino-phenyl)-ethyl]-amide	165-166	2-(3-Acetylamino-phenyl)-ethylamine

51		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid N'-phenyl-hydrazide	226-227	Phenyl-hydrazine
52		Pyridine-2-carboxylic acid N'-(4-methoxy-7-morpholin-4-yl-benzothiazole-2-carbonyl)-hydrazide	225-226	2-Picolinyl hydrazide
53		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid pyridin-4-ylamide	206-207	4-Amino-pyridine
54		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-thiophen-3-yl-ethyl)-amide	137-139	3-Thiophene-ethylamine
55		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide	160-163	3-(2-Aminoethyl)-pyridine
56		3,5-Dimethoxy-benzoic acid N'-(4-methoxy-7-morpholin-4-yl-benzothiazole-2-carbonyl)-hydrazide	146-148	3,5-Dimethoxy-benz-hydrazide





57		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide	120-122	3-Fluoro-phenyl-ethylamine
58		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	151-153	2-Fluoro-phenyl-ethylamine
59		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	150-153	4-Fluoro-phenyl-ethylamine
60		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide	106-108	2-(3-Trifluoro-methyl-phenyl)-ethylamine
61		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-p-tolyl-ethyl)-amide	136-138	4-Methyl-phenyl-ethylamine
62		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	153-154	2-(4-Chloro-phenyl)-ethylamine

63		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(2-chloro-phenyl)-ethyl]-amide	141-143	2-(2-Chloro-phenyl)-ethylamine
64		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide	99-101	3-Methoxy-phenylethyl-amine
65		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	109-111	3-Chlorophenyl-ethylamine
66		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(4-methoxy-phenyl)-2-oxo-ethyl]-amide	176-178	2-amino-4'-methoxy-aceto-phenone
67		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (phenyl-pyridin-2-yl-methyl)-amide	219-221	Phenyl-(2-pyridyl)-methylamine
68		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(4-methoxy-phenyl)-ethyl]-amide	69-71	4-Methoxy-phenylethyl-amine

69		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide	187-189	Benzo(b)thiophen-3-yl-methylamine
70		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (5-methyl-furan-2-ylmethyl)-amide	173-174	5-Methyl-furfuryl-amine
71		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-m-tolyl-ethyl)-amide	119-121	3-Methyl-phenethyl-amine
72		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-hydroxy-cyclohexyl)-amide	110-115	trans-2-Amino-cyclohexanol
73		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-chloro-thiophen-2-yl)-2-oxo-ethyl]-amide	125-127	2-(3-Chloro-thien-2-yl)-2-oxo-1-ethanamine
74		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-o-tolyl-ethyl)-amide	129-131	2-Methyl-phenethyl-amine


75		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-2-oxo-ethyl]-amide	206-208	2-Amino-1-(2,3-dihydro-benzo[1,4]-dioxin-6-yl)-ethanone
76		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-methyl-benzo[b]thiophen-2-yl)-2-oxo-ethyl]-amide	185-187	2-Amino-1-(3-methyl-benzo[b]-thiophen-2-yl)-ethanone
77		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [1-(4-methyl-thiazol-2-yl)-ethyl]-amide	175-176	alpha-Methyl-2-(4-methyl-thiazole)-methan-amine
78		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-oxo-2-thiophen-2-yl-ethyl)-amide	171-173	2-Amino-1-(2-thienyl) ethanone
79		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-oxo-2-thiophen-3-yl-ethyl)-amide	229-232	2-Amino-1-(3-thienyl) ethanone
80		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [1-(2-methyl-thiazol-4-yl)-ethyl]-amide	174-175	4-(1-Amino-ethyl)-2-methyl-thiazole



81		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (1-methyl-2-thiophen-2-yl-ethyl)-amide	127-129	2-(2-Amino-propyl)-thiophene
82		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (6-methyl-pyridin-3-yl)-amide	145-147	5-Amino-2-methylpyridine
83		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(5-amino-[1,3,4]thiadiazol-2-yl)sulfanyl]-ethyl)-amide	237-239	2Amino-5-[(2-aminoethyl)thio]-1,3,4-thiadiazole
84		4-Methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-benzofuran-2-yl-1-methyl-ethyl)-amide	144-146	2-(2-Aminopropyl)-benzofuran

Claims

## 1. Compounds of the general formula



wherein

5 R is

hydrogen,

-(CH<sub>2</sub>)<sub>n</sub>-phenyl, optionally substituted by halogen, lower alkyl, lower alkoxy, trifluoromethyl or -N(R')-C(O)-lower alkyl,

-(CH<sub>2</sub>)<sub>n</sub>-pyridinyl, optionally substituted by lower alkyl,

10 -(CH<sub>2</sub>)<sub>n</sub>-C<sub>3-6</sub>-cycloalkyl, optionally substituted by hydroxy,

-(CH<sub>2</sub>)<sub>n</sub>-N(R')-C<sub>3-6</sub>-cycloalkyl, optionally substituted by hydroxy,

-(CH<sub>2</sub>)<sub>n</sub>-benzo[1,3]-dioxolyl,

-(CR'<sub>2</sub>)<sub>n</sub>-thiophenyl, optionally substituted by lower alkyl,

-(CR'<sub>2</sub>)<sub>n</sub>-thiazolyl, optionally substituted by lower alkyl,

15 -(CH<sub>2</sub>)<sub>n</sub>-C(O)-thiophenyl, optionally substituted by halogen,

-(CH<sub>2</sub>)<sub>n</sub>-furanlyl, optionally substituted by lower alkyl,

-(CH<sub>2</sub>)<sub>n</sub>-C(O)-(CH<sub>2</sub>)<sub>n</sub>-thiophenyl,

-(CHR')<sub>n</sub>-benzofuran-2-yl,

-(CH<sub>2</sub>)<sub>n</sub>-benzo[b]thiophenyl, optionally substituted by lower alkyl,

20 -(CH<sub>2</sub>)<sub>n</sub>-N(R')-C(O)-phenyl, optionally substituted by halogen or lower alkoxy,

-(CH<sub>2</sub>)<sub>n</sub>-C(O)-phenyl, optionally substituted by lower alkoxy,

-(CH<sub>2</sub>)<sub>n</sub>-C(O)-2,3-dihydro-benzo[1,4]dioxin-6-yl,

-(CH<sub>2</sub>)<sub>n</sub>-N(R')-C(O)-pyridinyl,

-(CH<sub>2</sub>)<sub>n</sub>-tetrahydrofuranlyl,

25 -CH-bi-phenyl,

-CH(phenyl)-pyridinyl,

-(CH<sub>2</sub>)<sub>n</sub>-1-oxo-1,3-dihydro-isoindol-2-yl,

-(CH<sub>2</sub>)<sub>n</sub>-1,3-dioxo-1,3-dihydro-isoindol-2-yl,

-(CH<sub>2</sub>)<sub>n</sub>-CH(phenyl)-tetrahydropyranyl,  
-(CH<sub>2</sub>)<sub>n</sub>-1-oxo-1,2,3,4-tetrahydro-isoquinolin-3-yl or  
-(CH<sub>2</sub>)<sub>n</sub>-S-[1,3,4]thiazol-2-yl, optionally substituted by amino;

R' is hydrogen or lower alkyl, independently from each other in case R'<sub>2</sub>; and

5 n is 0, 1, 2, 3 or 4;

and pharmaceutically acceptable acid addition salts thereof.

2. Compounds of formula I in accordance with claim 1, wherein R is hydrogen.

3. A compound of formula I in accordance with claim 2, wherein the compound is  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid amide.

10 4. Compounds in accordance with claim 1, wherein R is -(CH<sub>2</sub>)<sub>n</sub>-phenyl, optionally  
substituted by halogen, lower alkoxy or lower alkyl.

5. Compounds in accordance with claim 4, wherein the compound is

4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid phenethyl-amide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 3-chloro-benzylamide,  
15 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 2-chloro-benzylamide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid 2-methoxy-benzylamide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(2-methoxy-phenyl)-  
ethyl]-amide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-fluoro-phenyl)-  
20 ethyl]-amide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(4-fluoro-phenyl)-  
ethyl]-amide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(4-chloro-phenyl)-  
ethyl]-amide,  
25 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(2-chloro-phenyl)-  
ethyl]-amide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-methoxy-phenyl)-  
ethyl]-amide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-chloro-phenyl)-  
30 ethyl]-amide or  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-m-tolyl-ethyl)-amide.

6. Compounds in accordance with claim 1, wherein R is  $-(CH_2)_n$ -pyridinyl.

7. Compounds in accordance with claim 6, wherein the compound is  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid pyridin-3-ylamide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (pyridin-2-ylmethyl)-amide  
5 or  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-pyridin-3-yl-ethyl)-  
amide.

8. Compounds in accordance with claim 1, wherein R is  $-(CHR')_n$ -thiophenyl or  
 $-(CH_2)_n$ -C(O)-thiophenyl, optionally substituted by halogen.


10 9. Compounds in accordance with claim 8, wherein the compound is  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-thiophen-2-yl-ethyl)-  
amide,  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (2-thiophen-3-yl-ethyl)-  
amide,  
15 4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [2-(3-chloro-thiophen-2-  
yl)-2-oxo-ethyl]-amide or  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid (1-methyl-2-thiophen-2-yl-  
ethyl)-amide.

20 10. Compounds in accordance with claim 1, wherein R is  $-(CHR')_n$ -thiazolyl,  
optionally substituted by lower alkyl.

11. Compounds in accordance with claim 10, wherein the compound is  
4-methoxy-7-morpholin-4-yl-benzothiazole-2-carboxylic acid [1-(4-methyl-thiazol-2-yl)-  
ethyl]-amide.

25 12. A process for preparing a compound of formula I as defined in claims 1 - 11,  
which processes comprise

a) reacting a compound of formula




with a compound of formula

- 36 -




to a compound of formula




wherein R is as defined in claim 1, or

5        b) cyclising a compound of formula



to a compound of formula



wherein R is as described in claim 1, and

10        if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

13. A compound according to any one of claims 1 to 11, whenever prepared by a process as claimed in claim 14 or by an equivalent method.

14. A medicament containing one or more compounds as claimed in any one of  
15        claims 1 to 11 and pharmaceutically acceptable excipients.

15. A medicament according to claim 14 for the treatment of diseases related to the adenosine receptor.

16. The use of a compound in any one of claims 1 to 11 for the treatment of diseases.

17. The use of a compound in any one of claims 1 to 11 for the manufacture of corresponding medicaments for the treatment of diseases related to the adenosine A<sub>2A</sub> receptor.

5        18. The invention as hereinbefore described.

\*\*\*

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 02/12907

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/428 A61K31/429 A61K31/44 A61P25/16 A61P25/28  
C07D277/82 C07D417/12 C07D409/12 C07D477/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 01 97786 A (HOFFMANN LA ROCHE) 27 December 2001 (2001-12-27) claims 1,19 -----	1-17

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

22 January 2003

Date of mailing of the international search report

29/01/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gettins, M

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 02/12907

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 18  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.2

Claims Nos.: 18

The scope of claim 18 "The invention as hereinbefore described" is either merely a repetition of claims 1-17 in which case it is superfluous or a fully unclear reference to the description (Art 6 PCT). In either case it has not been searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP 02/12907

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
W0 0197786	A	27-12-2001	
		AU 8181701 A	02-01-2002
		W0 0197786 A2	27-12-2001
		US 2002045615 A1	18-04-2002
<hr/>			